Israeli Drug Discount Plan For Pensioners

4 March 1996

The Labour and Social Affairs Com-mittee of Israel's Knesset has app-roved a plan requiring all sick funds to give discounts for prescription copayments to women aged over 60 and men over 65. It is also understood that the Ministry of Health plans to unify the funds' methods of copayment; the General Sick Fund's is based on volume of drugs dispensed, while most other funds use a percentage of cost method, usually 10%.

The government has also approved reimbursement of Betaseron (beta-interferon) for multiple sclerosis patients, involving special Treasury funding arrangements for the funds of about NIS20 million ($6.3 million). The MoH has also said that MS patients will pay the monthly copayment of NIS130 ($41.37), which equals the monthly copayment ceiling which GSF members pay for medicines in general.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight